CLAIMS

What is claimed is:

1. A compound of formula (I),

(R^2R^3)-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}-A^{18}-A^{19}-A^{20}-A^{21}-A^{22}-A^{23}-A^{24}-A^{25}-A^{26}-A^{27}-A^{28}-A^{29}-A^{30}-A^{31}-A^{32}-A^{33}-A^{34}-A^{35}-A^{36}-A^{37}-A^{38}-A^{39}-R^1 (SEQ ID NO:412),

(I)

wherein

A^7 is L-His, Ura, Paa, Pta, Amp, Tma-His, des-amino-His, or deleted;

A^8 is Ala, D-Ala, Aib, Acc, N-Me-Ala, N-Me-D-Ala or N-Me-Gly;

A^9 is Glu, N-Me-Glu, N-Me-Asp or Asp;

A^{10} is Gly, Acc, β-Ala or Aib;

A^{11} is Thr or Ser;

A^{12} is Phe, Acc, Aic, Aib, 3-Pal, 4- Pal, β-Nal, Cha, Trp or X^1-Phe;

A^{13} is Thr or Ser;

A^{14} is Ser or Aib;

A^{15} is Asp or Glu;

A^{16} is Val, Acc, Aib, Leu, Ile, Tle, Nle, Abu, Ala or Cha;

A^{17} is Ser or Thr;

A^{18} is Ser or Thr;

A^{19} is Tyr, Cha, Phe, 3-Pal, 4-Pal, Acc, β-Nal or X^1-Phe;

A^{20} is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Val, Phe or X^1-Phe;

A^{21} is Glu or Asp;

A^{22} is Gly, Acc, β-Ala, Glu or Aib;

A^{23} is Gln, Asp, Asn or Glu;

A^{24} is Ala, Aib, Val, Abu, Tle or Acc;

A^{25} is Ala, Aib, Val, Abu, Tle, Acc, Lys, Arg, hArg, Orn, HN-CH($(CH_2)_n$-N(R^{10}-R^{11}))-C(O) or NH-CH($(CH_2)_e$-X^3)-C(O);

A^{26} is Lys, Arg, hArg, Orn, HN-CH($(CH_2)_n$-N(R^{10}-R^{11}))-C(O) or NH-CH($(CH_2)_e$-X^3)-C(O);

A^{27} is Glu Asp, Leu, Aib or Lys;

A^{28} is Phe, Pal, β- Nal, X^1-Phe, Aic, Acc, Aib, Cha or Trp;

A^{29} is Ile, Acc, Aib, Leu, Nle, Cha, Tle, Val, Abu, Ala or Phe;

A^{30} is Ala, Aib or Acc;

A^{31} is Trp, β-Nal, 3-Pal, 4-Pal, Phe, Acc, Aib or Cha;

A^{32} is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Phe, X^1-Phe or Ala;

A^{33} is Val, Acc, Aib, Leu, Ile, Tle, Nle, Cha, Ala, Phe, Abu, Lys or X^1-Phe;

A^{34} is Lys, Arg, hArg, Orn, HN-CH($(CH_2)_n$-N(R^{10}-R^{11}))-C(O) or NH-CH($(CH_2)_e$-X^3)-C(O);

A^{35} is Gly, β-Ala, D-Ala, Gaba, Ava, NH-$(CH_2)_m$-C(O), Aib, Acc or a D-amino acid;

A^{36} is L-or D-Arg, D-or L-Lys, D-or L-hArg, D-or L-Orn, HN-CH($(CH_2)_n$-N(R^{10}-R^{11}))-C(O), NH-CH($(CH_2)_e$-X^3)-C(O) or deleted;

A^{37} is Gly, β-Ala, Gaba, Ava, Aib, Acc, Ado, Arg, Asp, Aun, Aec, NH-$(CH_2)_m$-C(O), HN-CH($(CH_2)_n$-N(R^{10}-R^{11}))-C(O), a D-amino acid, or deleted;

A^{38} is D-or L-Lys, D-or L-Arg, D-or L-hArg, D-or L-Orn, HN-CH($(CH_2)_n$-N(R^{10}-R^{11}))-C(O), NH-CH($(CH_2)_e$-X^3)-C(O), Ava, Ado, Aec or deleted;

A^{39} is D-or L-Lys, D-or L-Arg, HN-CH($(CH_2)_n$-N(R^{10}-R^{11}))-C(O), Ava, Ado, or Aec;

X^1 for each occurrence is independently selected from the group consisting of (C_1-C_6)alkyl, OH and halo;

R^1 is OH, NH_2, (C_1-C_{30}) alkoxy, or NH-X^2-CH_2-Z^0, wherein X^2 is a (C_1-C_{12}) hydrocarbon moiety, and Z^0 is H, OH, CO_2H or $CONH_2$;



X^3 is



or -C(O)-NHR[12], wherein X^4 is, independently for each occurrence, -C(O)-, -NH-C(O)- or -CH_2-, and wherein f is , independently for each occurrence, an integer from 1 to 29 inclusive;

each of R^2 and R^3 is independently selected from the group consisting of H, (C_1-C_{30})alkyl, (C_2-C_{30})alkenyl, phenyl(C_1-C_{30})alkyl, naphthyl(C_1-C_{30})alkyl, hydroxy(C_1-C_{30})alkyl, hydroxy(C_2-C_{30})alkenyl, hydroxyphenyl(C_1-C_{30})alkyl, and hydroxynaphthyl(C_1-C_{30})alkyl; or one of R^2 and R^3 is $(CH_3)_2$-N-C(↑)=N(+)$(CH_3)_2$, (C_1-C_{30})acyl, (C_1-C_{30})alkylsulfonyl, C(O)X^5,




; wherein Y is H, OH or NH_2; r is 0 to 4; q is 0 to 4; and X^5 is (C_1-C_{30})alkyl, (C_2-C_{30})alkenyl, phenyl(C_1-C_{30})alkyl, naphthyl(C_1-C_{30})alkyl, hydroxy(C_1-C_{30})alkyl, hydroxy(C_2-C_{30})alkenyl, hydroxyphenyl(C_1-C_{30})alkyl or hydroxynaphthyl(C_1-C_{30})alkyl;

e is, independently for each occurrence, an integer from 1 to 4 inclusive;

m is, independently for each occurrence, an integer from 5 to 24 inclusive;

n is, independently for each occurrence, an integer from 1 to 5, inclusive;

each of R^{10} and R^{11} is, independently for each occurrence, H, (C_1-C_{30})alkyl, (C_1-C_{30})acyl, (C_1-C_{30})alkylsulfonyl, -C((NH)(NH_2)) or



; and

R^{12} and R^{13} each is, independently for each occurrence, (C_1-C_{30})alkyl;

provided that:

when A^7 is Ura, Paa or Pta, then R^2 and R^3 are deleted;

when R^{10} is (C_1-C_{30})acyl, (C_1-C_{30})alkylsulfonyl, -C((NH)(NH_2)) or



, then R^{11} is H or (C_1-C_{30})alkyl;

(i) at least one amino acid of a compound of formula (I) is not the same as the native sequence of hGLP-1(7-36, -37 or -38)NH_2 or hGLP-1(7-36, -37 or -38)OH;

(ii) a compound of formula (I) is not an analogue of hGLP-1(7-36, -37 or -38)NH_2 or hGLP-1(7-36, -37 or -38)OH wherein a single position has been substituted by Ala;

(iii) a compound of formula (I) is not ($Arg^{26,34}$, Lys^{38})hGLP-1(7-38)-E, (Lys^{26}(N_ε-alkanoyl))hGLP-1(7-36, -37 or -38)-E, (Lys^{34}(N_ε-alkanoyl))hGLP-1(7-36, -37 or -38)-E, ($Lys^{26,34}$-bis(N_ε-alkanoyl))hGLP-1(7-36, -37 or -38)-E, (Arg^{26}, Lys^{34}(N_ε-alkanoyl))hGLP-1(8-36, -37 or -38)-E, ($Arg^{26,34}$, Lys^{36}(N_ε-alkanoyl))hGLP-1(7-36, -37 or -38)-E or ($Arg^{26,34}$, Lys^{38}(N_ε-alkanoyl))hGLP-1(7-38)-E, wherein E is -OH or -NH_2;

(iv) a compound of formula (I) is not Z^1-hGLP-1(7-36, -37 or -38)-OH, Z^1-hGLP-1(7-36, -37 or

-38)-NH_2, wherein Z^1 is selected from the group consisting of:

(e) (Arg^{26}), (Arg^{34}), ($Arg^{26,34}$), (Lys^{36}), (Arg^{26}, Lys^{36}), (Arg^{34}, Lys^{36}), (D-Lys^{36}), (Arg^{36}), (D-Arg^{36}), ($Arg^{26,34}$, Lys^{36}) or ($Arg^{26,36}$, Lys^{34});

(f) (Asp^{21});

(g) at least one of (Aib^8), (D-Ala^8) and (Asp^9); and

(h) (Tyr^7), (N-acyl-His^7), (N-alkyl-His^7), (N-acyl-D-His^7) or (N-alkyl-D-His^7);

(v) a compound of formula (I) is not a combination of any two of the substitutions listed in groups (a) to (d); and

(vi) a compound of formula (I) is not (N-Me-Ala^8)hGLP-1(8-36 or -37), (Glu^{15})hGLP-1(7-36 or -37), (Asp^{21})hGLP-1(7-36 or -37) or (Phe^{31})hGLP-1(7-36 or -37) or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, wherein A^{11} is Thr; A^{13} is Thr; A^{15} is Asp; A^{17} is Ser; A^{18} is Ser; A^{21} is Glu; A^{23} is Gln or Glu; A^{27} is Glu; A^{31} is Trp; or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 2, wherein A^9 is Glu, N-Me-Glu or N-Me-Asp; A^{12} is Phe, Acc or Aic; A^{16} is Val, Acc or Aib; A^{19} is Tyr; A^{20} is Leu, Acc or Cha; A^{24} is Ala, Aib or Acc; A^{25} is Ala, Aib, Acc, Lys, Arg, hArg, Orn, HN-CH($(CH_2)_n$-N($R^{10}R^{11}$))-C(O) or HN-CH($(CH_2)_e$-X^3)-C(O); A^{28} is Phe; A^{29} is Ile or Acc; A^{30} is Ala or Aib; A^{32} is Leu, Acc or Cha: and A^{33} is Val or Acc; or a pharmaceutically acceptable salt thereof.

4. A compound according to claim 3, wherein A^8 is Ala, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A^{10} is Gly; A^{12} is Phe, A6c or A5c; A^{16} is Val, A6c or A5c: A^{20} is Leu, A6c, A5c or Cha; A^{22} is Gly, β-Ala or Aib; A^{24} is Ala or Aib; A^{29} is Ile, A6c or A5c; A^{32} is Leu, A6c, A5c or Cha; A^{33} is Val, A6c or A5c; A^{35} is Aib, β-Ala, Ado, A6c, A5c or Gly; and A^{37} is Gly, Aib, β-Ala, Ado, D-Ala or deleted; or a pharmaceutically acceptable salt thereof.

5. A compound according to claim 4 or a pharmaceutically acceptable salt thereof, wherein X^4 for each occurrence is -C(O)-; e for each occurrence is independently 1 or 2; and R^1 is OH or NH_2.

6. A compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein R^2 is H and R^3 is (C_1-C_{30})alkyl, (C_2-C_{30})alkenyl, (C_1-C_{30})acyl, (C_1-C_{30})alkylsulfonyl,



or



7. A compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein R^{10} is (C_1-C_{30})acyl, (C_1-C_{30})alkylsulfonyl or



, and R^{11} is H.

8. A compound according to claim 7 or a pharmaceutically acceptable salt thereof, wherein R^{10} is (C_4-C_{20})acyl, (C_4-C_{20})alkylsulfonyl or



9. A compound according to claim 1 wherein said compound is

($Aib^{8,35}$)hGLP-1(7-36)NH_2 (SEQ ID NO:2),

((N^{α}-HEPES-His)^7, $Aib^{8,35}$)hGLP-1(7-36)NH_2 (SEQ ID NO:3),

((N^{α}-HEPA-His)^7, $Aib^{8,35}$)hGLP-1(7-36)NH_2 (SEQ ID NO:4),

(Aib^8, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:5),

($Aib^{8,35}$, $Arg^{26,34}$, Lys^{36}(N_{ε}-tetradecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:6),

($Aib^{8,35}$, Arg^{26}, Lys^{34}(N_{ε}-tetradecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:7),

(Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N_ε-tetradecanoyl))hGLP-1(7-38)NH_2 (SEQ ID NO:8),
(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_ε-decanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:9),
(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_ε-dodecanesulfonyl))hGLP-1(7-36)NH_2 (SEQ ID NO:10),
(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_ε-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:11),
(Aib^{8,35}, Arg^{26,34}, Asp^{36}(1-(4-tetradecyl-piperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:12),
(Aib^{8,35}, Arg^{26,34}, Asp^{36}(1-tetradecylamino))hGLP-1(7-36)NH_2 (SEQ ID NO:13),
(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_ε-tetradecanoyl), β-Ala^{37})hGLP-1(7-37)-OH (SEQ ID NO:14) or
(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_ε-tetradecanoyl))hGLP-1(7-36)-OH (SEQ ID NO:15), or a pharmaceutically acceptable salt thereof.

10. A compound according to claim 9 wherein said compound is
(Aib^{8,35})hGLP-1(7-36)NH_2 (SEQ ID NO:2),
(Aib^{8}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:5),
(Aib^{8,35}, Arg^{26}, Lys^{34}(N_ε-tetradecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:7),
(Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N_ε-tetradecanoyl))hGLP-1(7-38)NH_2 (SEQ ID NO:8),
(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_ε-decanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:9), or
(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N_ε-tetradecanoyl), β-Ala^{37})hGLP-1(7-37)-OH (SEQ ID NO:14), or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

12. A method of eliciting an agonist effect from a GLP-1 receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

13. A method for treating a disease selected from the group consisting of Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis and neurodegenerative disease,

in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

14. A method according to claim 13 wherein said disease is Type I diabetes or Type II diabetes.

15. A compound according to claim 1 wherein said compound is

(Aib^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:71);

(β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:72);

((N$^{\alpha}$-Me-His)^{7}, Aib^{8,35})hGLP-1(7-36)NH_2 (SEQ ID NO:73);

((N$^{\alpha}$-Me-His)^{7}, Aib^{8}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:74);

((N$^{\alpha}$-Me-His)^{7}, Aib^{8,35}, Arg ^{26,34})hGLP-1(7-36)NH_2 (SEQ ID NO:75);

((N$^{\alpha}$-Me-His)^{7}, Aib^{8}, Arg ^{26,34}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:76);

(Aib^{8}, A6c^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:77);

(Aib^{8}, A5c^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:78);

(Aib^{8}, D-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:79);

(Aib^{8,35}, A6c^{32})hGLP-1(7-36)NH_2 (SEQ ID NO:16);

(Aib^{8,35}, A5c^{32})hGLP-1(7-36)NH_2 (SEQ ID NO:80);

(Aib^{8,35}, Glu^{23})hGLP-1(7-36)NH_2 (SEQ ID NO:17);

(Aib ^{8,24,35})hGLP-1(7-36)NH_2 (SEQ ID NO:18);

(Aib ^{8,30,35})hGLP-1(7-36)NH_2 (SEQ ID NO:81);

(Aib ^{8,25,35})hGLP-1(7-36)NH_2 (SEQ ID NO:82);

(Aib^{8,35}, A6c^{16,20})hGLP-1(7-36)NH_2 (SEQ ID NO:83);

(Aib^{8,35}, A6c^{16,29,32})hGLP-1(7-36)NH_2 (SEQ ID NO:84);

(Aib^{8,35}, A6c^{20,32})hGLP-1(7-36)NH_2 (SEQ ID NO:85);

(Aib^{8,35}, A6c^{20})hGLP-1(7-36)NH_2 (SEQ ID NO:86);

(Aib^{8,35}, Lys^{25})hGLP-1(7-36)NH_2 (SEQ ID NO:87);

(Aib^{8,24,35}, A6c^{20})hGLP-1(7-36)NH_2 (SEQ ID NO:88);

(Aib^{8,35}, A6c^{29,32})hGLP-1(7-36)NH_2 (SEQ ID NO:89);

(Aib^{8,24,35}, A6c^{29,32})hGLP-1(7-36)NH_2 (SEQ ID NO:90);

(Aib^{8,35}, A6c^{12})hGLP-1(7-36)NH_2 (SEQ ID NO:91);

(Aib^{8,35}, Cha^{20})hGLP-1(7-36)NH_2 (SEQ ID NO:92);

(Aib^{8,35}, A6c^{33})hGLP-1(7-36)NH_2 (SEQ ID NO:93);

(Aib^{8,35}, A6c^{20,32})hGLP-1(7-36)NH_2 (SEQ ID NO:85);

(Aib^{8}, A6c^{16,20}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:94);

(Aib^{8,35}, β-Ala^{22})hGLP-1(7-36)NH_2 (SEQ ID NO:95);

(Aib^{8,22,35})hGLP-1(7-36)NH_2 (SEQ ID NO:96);

(Aib^{8,35}, Glu^{23}, A6c^{32})hGLP-1(7-36)NH_2 (SEQ ID NO:19);

(Aib^{8,24,35}, Glu^{23}, A6c^{32})hGLP-1(7-36)NH_2 (SEQ ID NO:97);

(Aib^{8,24,25,35}, Glu^{23}, A6c^{32})hGLP-1(7-36)NH_2 (SEQ ID NO:98);

(Aib^{8,24,25,35}, A6c^{16,20,32}, Glu^{23},)hGLP-1(7-36)NH_2 (SEQ ID NO:99);

(Aib^{8}, A6c^{32}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:100);

(Aib^{8}, A5c^{32}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:101);

(Aib^{8}, Glu^{23}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:20);

(Aib^{8,24}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:102);

53: (Aib^{8,30}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:103);

(Aib^{8,25}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:104);

(Aib^{8}, A6c^{16,20}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:94);

(Aib^{8}, A6c^{16,29,32}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:105);

(Aib^{8}, A6c^{20,32}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:106);

(Aib^{8}, A6c^{20}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:107);

(Aib^{8}, Lys^{25}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:108);

(Aib^{8,24}, A6c^{20}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:109);

(Aib^{8}, A6c^{29,32}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:110);

(Aib^{8,24}, A6c^{29,32}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:111);

(Aib^{8}, A6c^{12}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:112);

(Aib^{8}, Cha^{20}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:113);

(Aib^{8}, A6c^{33}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:114);

(Aib^{8}, A6c^{20,32}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:106);

(Aib^{8}, β-Ala^{22,35})hGLP-1(7-36)NH_2 (SEQ ID NO:115);

(Aib^{8,22}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:116);

(Aib^{8}, Glu^{23}, A6c^{32}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:117);

(Aib[8,24], Glu[23], A6c[32], β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:118);

(Aib[8,24], Glu[23], A6c[32], Lys[34](N$_\varepsilon$-octanoyl), β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:119);

(Aib[8,24,25], Glu[23], A6c[32], β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:120);

(Aib[8,24,25], A6c[16,20,32], Glu[23], β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:121);

(Aib[8,35], D-Arg[36])hGLP-1(7-36)NH_2 (SEQ ID NO:122);

(Aib[8,35], D-Lys[36])hGLP-1(7-36)NH_2 (SEQ ID NO:123);

(Aib[8], β-Ala[35], D-Arg[36])hGLP-1(7-36)NH_2 (SEQ ID NO:124);

(Aib[8], β-Ala[35], D-Lys[36])hGLP-1(7-36)NH_2 (SEQ ID NO:125);

(Aib[8,35], Arg[26,34],)hGLP-1(7-36)NH_2 (SEQ ID NO:21);

(Aib[8], Arg[26,34], β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:126);

(Aib[8,35], Arg[25,26,34])hGLP-1(7-36)NH_2 (SEQ ID NO:127);

(Aib[8], Arg[25,26,34], β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:128);

(Aib[8], Arg[26,34], β-Ala[35], Lys[36](N$^\varepsilon$-tetradecanoyl))hGLP-1(7-36)OH (SEQ ID NO:129);

(Aib[8,35], Arg[26,34], Lys[36](N$^\varepsilon$-tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:130);

(Aib[8,35,37], Arg[26,34], Lys[36](N$^\varepsilon$-tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:131);

(Aib[8,35], Arg[26,34], Lys[36](N$^\varepsilon$-tetradecanoyl), D-Ala[37])hGLP-1(7-37)OH (SEQ ID NO:132);

(Aib[8,35,37], Arg[26,34], Lys[38](N$^\varepsilon$-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:133);

(Aib[8,35], Arg[26,34], β-Ala[37], Lys[38](N$^\varepsilon$-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:134);

(Aib[8,35], Arg[26,34], Lys[38](N$^\varepsilon$-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:135);

(Aib[8], Arg[26,34], Lys[36](N$^\varepsilon$-tetradecanoyl), β-Ala[37])hGLP-1(7-37)OH (SEQ ID NO:136);

(Aib[8,37], Arg[26,34], Lys[36](N$^\varepsilon$-tetradecanoyl))hGLP-1(7-37)OH (SEQ ID NO:137);

(Aib[8,35], Arg[26,34], Ado[37])hGLP-1(7-37)OH (SEQ ID NO:138);

(Aib[8,35], Arg[26,34], Ado[37])hGLP-1(7-37)NH_2 (SEQ ID NO:139);

(Aib[8], Arg[26,34], Lys[36](N$^\varepsilon$-tetradecanoyl), D-Ala[37])hGLP-1(7-37)OH (SEQ ID NO 140);

(Aib[8,37], Arg[26,34], Lys[38](N$^\varepsilon$-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:141);

(Aib[8], Arg[26,34], β-Ala[37], Lys[38](N$^\varepsilon$-tetradecanoyl))hGLP-1(7-38)OH (SEQ ID NO:142);

(Aib[8,35], Lys[26](N$^\varepsilon$-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:143);

(Aib[8,35], Lys[26](N$^\varepsilon$-tetradecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:144);

(Aib[8,35], Lys[26](N$^\varepsilon$-hexadecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:145);

(Aib[8], Lys[26](N$^\varepsilon$-octanoyl), β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:146);

(Aib[8], Lys[26](N$^\varepsilon$-tetradecanoyl), β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:147);

(Aib^{8}, Lys^{26}(N$^{\varepsilon}$-hexadecanoyl), β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:148);

(Aib^{8,35}, Lys^{26}(N$^{\varepsilon}$-octanoyl), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:149);

(Aib^{8,35}, Lys^{26}(N$^{\varepsilon}$-tetradecanoyl), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:150);

(Aib^{8,35}, Lys^{26}(N$^{\varepsilon}$-hexadecanoyl), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:151);

(Aib^{8,35}, Lys^{26}(N$^{\varepsilon}$-decanoyl), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:152);

(Aib^{8,35}, Lys^{25}, Lys^{26}(N$^{\varepsilon}$-octanoyl), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:153);

(Aib^{8,35}, Lys^{25}, Lys^{26}(N$^{\varepsilon}$-tetradecanoyl), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:154);

(Aib^{8,35}, Lys^{25}, Lys^{26}(N$^{\varepsilon}$-hexadecanoyl), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:155);

(Aib^{8,35}, Arg^{25,34}, Lys^{26}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:156);

(Aib^{8,35}, Arg^{25,34}, Lys^{26}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:157);

(Aib^{8,35}, Arg^{25,34}, Lys^{26}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:158);

(Aib^{8,35}, Arg^{25,34}, Lys^{26}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:159);

(Aib^{8}, Lys^{26}(N$^{\varepsilon}$-octanoyl), Arg^{34}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:160);

(Aib^{8}, Lys^{26}(N$^{\varepsilon}$-tetradecanoyl), Arg^{34}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:161);

(Aib^{8}, Lys^{26}(N$^{\varepsilon}$-hexadecanoyl), Arg^{34}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:162);

(Aib^{8}, Lys^{26}(N$^{\varepsilon}$-decanoyl), Arg^{34}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:163);

(Aib^{8,35}, Lys^{34}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:164);

(Aib^{8,35}, Lys^{34}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:165);

(Aib^{8,35}, Lys^{34}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:166);

(Aib^{8,35}, Arg^{26}, Lys^{34}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:167);

(Aib^{8,35}, Arg^{26}, Lys^{34}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:168);

(Aib^{8,35}, Arg^{26}, Lys^{34}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:169);

(Aib^{8,35}, Arg^{25,26}, Lys^{34}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:170);

(Aib^{8,35}, Arg^{25,26}, Lys^{34}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:171);

(Aib^{8,35}, Arg^{25,26}, Lys^{34}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:172);

(Aib^{8,35}, Arg^{25,26}, Lys^{34}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:173);

(Aib^{8,35}, Lys^{25}, Arg^{26}, Lys^{34}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:174);

(Aib^{8,35}, Lys^{25}, Arg^{26}, Lys^{34}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:175):

(Aib^{8,35}, Lys^{25}, Arg^{26}, Lys^{34}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:176);

(Aib^{8,35}, Lys^{36}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:177);

(Aib^{8,35}, Lys^{36}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:178);

(Aib^{8,35}, Lys^{36}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:179);

(Aib^{8,35}, Arg^{26}, Lys^{36}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:180);

(Aib^{8,35}, Arg^{26}, Lys^{36}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:181);

(Aib^{8,35}, Arg^{26}, Lys^{36}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:182);

(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:183);

(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:184);

(Aib^{8,35}, Arg^{26,34}, Lys^{38}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-38)NH$_2$ (SEQ ID NO:185);

(Aib^{8,35}, Arg^{26,34}, Lys^{38}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-38)NH$_2$ (SEQ ID NO:186);

(Aib^{8,35}, Arg^{26,34}, Lys^{38}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-38)NH$_2$ (SEQ ID NO:187);

(Aib^{8,35}, Arg^{26,34}, Lys^{38}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-38)NH$_2$ (SEQ ID NO:188);

(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-38)NH$_2$ (SEQ ID NO:189);

(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-38)NH$_2$ (SEQ ID NO:190);

(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-38)NH$_2$ (SEQ ID NO:191);

(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-38)NH$_2$ (SEQ ID NO:192);

(Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-38)NH$_2$ (SEQ ID NO:193);

(Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-38)NH$_2$ (SEQ ID NO:194);

(Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-38)NH$_2$ (SEQ ID NO:195);

(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-38)NH$_2$ (SEQ ID NO:189);

(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-38)NH$_2$ (SEQ ID NO:190);

(Aib^{8,35,37}, Arg2^{5,26,34}, Lys^{38}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-38)NH$_2$ (SEQ ID NO:191);

(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-38)NH$_2$ (SEQ ID NO:192);

(Aib^{8,35}, Lys^{25}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:196);

(Aib^{8,35}, Lys^{25}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:197);

(Aib^{8,35}, Lys^{25}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:198);

(Aib^{8,35}, Arg^{25,26,34}, Lys^{36}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:199);

(Aib^{8,35}, Arg^{25,26,34}, Lys^{36}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:200);

(Aib^{8,35}, Arg^{25,26,34}, Lys^{36}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:201);

(Aib^{8,35}, Arg^{25,26,34}, Lys^{36}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:202);

(Aib^{8}, Lys^{34}(N$^{\varepsilon}$-octanoyl), β-Ala^{35})hGLP-1(7-36)NH$_2$ (SEQ ID NO:203);

(Aib^{8}, Lys^{34}(N$^{\varepsilon}$-tetradecanoyl), β-Ala^{35})hGLP-1(7-36)NH$_2$ (SEQ ID NO:204);

(Aib^{8}, Lys^{34}(N$^{\varepsilon}$-hexadecanoyl), β-Ala^{35})hGLP-1(7-36)NH$_2$ (SEQ ID NO:205);

(Aib[8], A6c[32], Lys[34](Nε-octanoyl), β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:206);

(Aib[8], Glu[23], Lys[34](Nε-octanoyl), β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:207);

(Aib[8], Glu[23], A6c[32], Lys[34](Nε-octanoyl), β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:208);

(Aib[8], Arg[26], Lys[34](Nε-octanoyl), β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:209);

(Aib[8], Arg[26], Lys[34](Nε-tetradecanoyl), β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:210);

(Aib[8], Arg[26], Lys[34](Nε-hexadecanoyl), β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:211);

(Aib[8], Arg[26], Lys[34](Nε-decanoyl), β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:212);

(Aib[8], Arg[25,26], Lys[34](Nε-octanoyl), β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:213);

(Aib[8], Arg[25,26], Lys[34](Nε-tetradecanoyl), β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:214);

(Aib[8], Arg[25,26], Lys[34](Nε-hexadecanoyl), β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:215);

(Aib[8], Arg[25,26], Lys[34](Nε-decanoyl), β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:216);

(Aib[8], Lys[25], Arg[26], Lys[34](Nε-octanoyl), β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:217);

(Aib[8], Lys[25], Arg[26], Lys[34](Nε-tetradecanoyl), β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:218);

(Aib[8], Lys[25], Arg[26], Lys[34](Nε-hexadecanoyl), β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:219);

(Aib[8], β-Ala[35], Lys[36](Nε-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:220);

(Aib[8], β-Ala[35], Lys[36](Nε-tetradecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:221);

(Aib[8], β-Ala[35], Lys[36](Nε-hexadecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:222);

(Aib[8], Arg[26], β-Ala[35], Lys[36](Nε-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:223);

(Aib[8], Arg[26], β-Ala[35], Lys[36](Nε-tetradecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:224);

(Aib[8], Arg[26], β-Ala[35], Lys[36](Nε-hexadecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:225);

(Aib[8], Arg[26,34], β-Ala[35], Lys[36](Nε-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:226);

(Aib[8], Arg[26,34], β-Ala[35], Lys[36](Nε-tetradecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:227);

(Aib[8], Arg[26,34], β-Ala[35], Lys[36](Nε-hexadecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:228);

(Aib[8], Arg[26,34], β-Ala[35], Lys[36](Nε-decanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:229);

(Aib[8], Lys[25], Arg[26,34], β-Ala[35], Lys[36](Nε-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:230);

(Aib[8], Lys[25], Arg[26,34], Lys[36](Nε-tetradecanoyl), β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:231);

(Aib[8], Lys[25], Arg[26,34], β-Ala[35], Lys[36](Nε-hexadecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:232);

(Aib[8], Arg[25,26,34], β-Ala[35], Lys[36](Nε-octanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:233);

(Aib[8], Arg[25,26,34], β-Ala[35], Lys[36](Nε-tetradecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:234);

(Aib[8], Arg[25,26,34], β-Ala[35], Lys[36](Nε-hexadecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:235);

(Aib[8], Arg[25,26,34], β-Ala[35], Lys[36](Nε-decanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:236);

(Aib^{8,35}, Lys^{26}(N$^{\varepsilon}$-octanoyl), A6c^{32}, Arg^{34})hGLP-1(7-36)NH$_2$ (SEQ ID NO:237);

(Aib^{8,35}, Lys^{26}(N$^{\varepsilon}$-tetradecanoyl), A6c^{32}, Arg^{34})hGLP-1(7-36)NH$_2$ (SEQ ID NO:238);

(Aib^{8,35}, Lys^{26}(N$^{\varepsilon}$-hexadecanoyl), A6c^{32}, Arg^{34})hGLP-1(7-36)NH$_2$ (SEQ ID NO:239);

(Aib^{8,35}, A6c^{32}, Lys^{34}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:240);

(Aib^{8,35}, A6c^{32}, Lys^{34}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:241);

(Aib^{8,35}, A6c^{32}, Lys^{34}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:242);

(Aib^{8,35}, Arg^{26}, A6c^{32}, Lys^{34}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:243);

(Aib^{8,35}, Arg^{26}, A6c^{32}, Lys^{34}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:244);

(Aib^{8,35}, A6c^{32}, Lys^{36}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:245);

(Aib^{8,35}, A6c^{32}, Lys^{36}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:246);

(Aib^{8,35}, A6c^{32}, Lys^{36}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:247);

(Aib^{8,35}, Arg^{26}, A6c^{32}, Lys^{36}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:248);

(Aib^{8,35}, Arg^{26}, A6c^{32}, Lys^{36}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:249);

(Aib^{8,35}, Arg^{26}, A6c^{32}, Lys^{36}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:250);

(Aib^{8,35}, Arg^{26,34}, A6c^{32}, Lys^{36}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:251);

(Aib^{8,35}, Arg^{26,34}, A6c^{32}, Lys^{36}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:252);

(Aib^{8,35}, Arg^{26,34}, A6c^{32}, Lys^{36}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:253);

(Aib^{8,35}, Arg^{26,34}, A6c^{32}, Lys^{36}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:254);

(Aib^{8,24,35}, Lys^{26}(N$^{\varepsilon}$-octanoyl), Arg^{34})hGLP-1(7-36)NH$_2$ (SEQ ID NO:255);

(Aib^{8,24,35}, Lys^{26}(N$^{\varepsilon}$-tetradecanoyl), Arg^{34})hGLP-1(7-36)NH$_2$ (SEQ ID NO:256);

(Aib^{8,24,35}, Lys^{26}(N$^{\varepsilon}$-hexadecanoyl), Arg^{34})hGLP-1(7-36)NH$_2$ (SEQ ID NO:257);

(Aib^{8,24,35}, Arg^{26}, Lys^{34}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:258);

(Aib^{8,24,35}, Arg^{26}, Lys^{34}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:259);

(Aib^{8,24,35}, Arg^{26}, Lys^{34}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:260);

(Aib^{8,24,35}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:261);

(Aib^{8,24,35}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:262);

(Aib^{8,24,35}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:263);

(Aib^{8,24,35}, Glu^{23}, A6c^{32}, Lys^{34}(N$_{\varepsilon}$-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:264);

(Aib^{8,35}, Glu^{23}, Lys^{26}(N$^{\varepsilon}$-octanoyl), Arg^{34})hGLP-1(7-36)NH$_2$ (SEQ ID NO:265);

(Aib^{8,35}, Glu^{23}, Lys^{26}(N$^{\varepsilon}$-tetradecanoyl), Arg^{34})hGLP-1(7-36)NH$_2$ (SEQ ID NO:266);

(Aib^{8,35}, Glu^{23}, Lys^{26}(N$^{\varepsilon}$-hexadecanoyl), Arg^{34})hGLP-1(7-36)NH$_2$ (SEQ ID NO:267);

(Aib^{8,35}, Glu^{23}, Lys^{34}(Nε-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:268);

(Aib^{8,35}, Glu^{23}, A6c^{32}, Lys^{34}(Nε-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:269);

(Aib^{8,35}, Glu^{23}, Arg^{26}, Lys^{34}(Nε-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:270);

(Aib^{8,35}, Glu^{23}, Arg^{26}, Lys^{34}(Nε-tetradecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:271);

(Aib^{8,35}, Glu^{23}, Arg^{26}, Lys^{34}(Nε-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:272);

(Aib^{8,35}, Glu^{23}, Lys^{36}(Nε-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:273);

(Aib^{8,35}, Glu^{23}, Lys^{36}(Nε-tetradecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:274);

(Aib^{8,35}, Glu^{23}, Lys^{36}(Nε-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:275);

(Aib^{8,35}, Glu^{23}, Arg^{26,34}, Lys^{36}(Nε-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:276);

(Aib^{8,35}, Glu^{23}, Arg^{26,34}, Lys^{36}(Nε-tetradecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:277);

(Aib^{8,35}, Glu^{23}, Arg^{26,34}, Lys^{36}(Nε-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:278);

(Aib^{8,30,35}, Lys^{26}(Nε-octanoyl), Arg^{34})hGLP-1(7-36)NH$_2$ (SEQ ID NO:279);

(Aib^{8,30,35}, Lys^{26}(Nε-tetradecanoyl), Arg^{34})hGLP-1(7-36)NH$_2$ (SEQ ID NO:280);

(Aib^{8,30,35}, Lys^{26}(Nε-hexadecanoyl), Arg^{34})hGLP-1(7-36)NH$_2$ (SEQ ID NO:281);

(Aib^{8,30,35}, Arg^{26}, Lys^{34}(Nε-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:282);

(Aib^{8,30,35}, Arg^{26}, Lys^{34}(Nε-tetradecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:283);

(Aib^{8,30,35}, Arg^{26}, Lys^{34}(Nε-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:284);

(Aib^{8,30,35}, Arg^{26,34}, Lys^{36}(Nε-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:285);

(Aib^{8,30,35}, Arg^{26,34}, Lys^{36}(Nε-tetradecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:286);

(Aib^{8,30,35}, Arg^{26,34}, Lys^{36}(Nε-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:287);

(Aib^{8,35}, Glu^{23}, A6c^{32}, Lys^{36}(Nε-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:288);

(Aib^{8,35}, Glu^{23}, A6c^{32}, Lys^{36}(Nε-tetradecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:289);

(Aib^{8,35}, Glu^{23}, A6c^{32}, Lys^{36}(Nε-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:290);

(Aib^{8,35}, Glu^{23}, Arg^{26,34}, A6c^{32}, Lys^{36}(Nε-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:291);

(Aib^{8,35}, Glu^{23}, Arg^{26,34}, A6c^{32}, Lys^{36}(Nε-tetradecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:292);

(Aib^{8,35}, Glu^{23}, Arg^{26,34}, A6c^{32}, Lys^{36}(Nε-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:293);

(Aib^{8,24,35}, Glu^{23}, Arg^{26,34}, A6c^{32}, Lys^{36}(Nε-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:294);

(Aib^{8,24,35}, Glu^{23}, Arg^{26,34}, A6c^{32}, Lys^{36}(Nε-tetradecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:295);

(Aib^{8,24,35}, Glu^{23}, Arg^{26,34}, A6c^{32}, Lys^{36}(Nε-hexadecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:296);

(Aib^{8,24,30,35}, Glu^{23}, Arg^{26,34}, A6c^{32}, Lys^{36}(Nε-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:297);

(Aib^{8,24,30,35}, Glu^{23}, Arg^{26,34}, A6c^{32}, Lys^{36}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:298);

(Aib^{8,24,30,35}, Glu^{23}, Arg^{26,34}, A6c^{32}, Lys^{36}(N$^{\varepsilon}$-hexadecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:299);

((N$^{\alpha}$-HEPES-His)^{7}, Aib^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:300);

((N$^{\alpha}$-HEPES-His)^{7}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:301);

((N$^{\alpha}$-HEPES-His)^{7}, Aib^{8}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:302);

((N$^{\alpha}$-HEPA-His)^{7}, Aib^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:303);

((N$^{\alpha}$-HEPA-His)^{7}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:304);

((N$^{\alpha}$-HEPA-His)^{7}, Aib^{8}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:305);

((N$^{\alpha}$-tetradecanoyl-His)^{7}, Aib^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:306);

((N$^{\alpha}$-tetradecanoyl-His)^{7}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:307);

((N$^{\alpha}$-tetradecanoyl-His)^{7}, Aib^{8,35})hGLP-1(7-36)NH_2 (SEQ ID NO:308);

((N$^{\alpha}$-tetradecanoyl-His)^{7}, Aib^{8}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:309);

((N$^{\alpha}$-tetradecanoyl-His)^{7}, Arg^{26,34}, Aib^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:310);

((N$^{\alpha}$-tetradecanoyl-His)^{7}, Arg^{26,34}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:311);

((N$^{\alpha}$-tetradecanoyl-His)^{7}, Aib^{8,35}, Arg^{26,34})hGLP-1(7-36)NH_2 (SEQ ID NO:312);

((N$^{\alpha}$-tetradecanoyl-His)^{7}, Aib^{8}, Arg^{26,34}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:313);

((N$^{\alpha}$-tetradecanoyl-His)^{7}, Arg^{25,26,34}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:314);

((N$^{\alpha}$-tetradecanoyl-His)^{7}, Aib^{8,35}, Arg^{25,26,34})hGLP-1(7-36)NH_2 (SEQ ID NO:315);

((N$^{\alpha}$-tetradecanoyl-His)^{7}, Aib^{8}, Arg^{25,26,34}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:316);

(Aib^{8,35}, Lys^{26}(N$^{\varepsilon}$-octanesulfonyl), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:317);

(Aib^{8,35}, Lys^{26}(N$^{\varepsilon}$-dodecanesulfonyl), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:318);

(Aib^{8,35}, Lys^{26}(N$^{\varepsilon}$-hexadecanesulfonyl), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:319);

(Aib^{8,35}, Arg^{26}, Lys^{34}(N$^{\varepsilon}$-octanesulfonyl))hGLP-1(7-36)NH_2 (SEQ ID NO:320);

(Aib^{8,35}, Arg^{26}, Lys^{34}(N$^{\varepsilon}$-dodecanesulfonyl))hGLP-1(7-36)NH_2 (SEQ ID NO:321);

(Aib^{8,35}, Arg^{26}, Lys^{34}(N$^{\varepsilon}$-hexadecanesulfonyl))hGLP-1(7-36)NH_2 (SEQ ID NO:322);

(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-octanesulfonyl))hGLP-1(7-36)NH_2 (SEQ ID NO:323);

(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-hexadecanesulfonyl))hGLP-1(7-36)NH_2 (SEQ ID NO:324);

(Aib^{8,35}, Asp^{26}(1-(4-decylpiperazine)), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:325);

(Aib^{8,35}, Asp^{26}(1-(4-dodecylpiperazine)), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:326);

(Aib^{8,35}, Asp^{26}(1-(4-tetradecylpiperazine)), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:327);

(Aib^{8,35}, Asp^{26}(1-(4-hexadecylpiperazine)), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:328);

(Aib^{8,35}, Arg^{26}, Asp^{34}(1-(4-decylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:329);

(Aib^{8,35}, Arg^{26}, Asp^{34}(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:330);

(Aib^{8,35}, Arg^{26}, Asp^{34}(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:331);

(Aib^{8,35}, Arg^{26}, Asp^{34}(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:332);

(Aib^{8,35}, Arg^{26,34}, Asp^{36}(1-(4-decylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:333);

(Aib^{8,35}, Arg^{26,34}, Asp^{36}(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:334);

(Aib^{8,35}, Arg^{26,34}, Asp^{36}(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:335);

(Aib^{8,35}, Arg^{26,34}, Asp^{38}(1-(4-decylpiperazine)))hGLP-1(7-38)NH_2 (SEQ ID NO:336);

(Aib^{8,35}, Arg^{26,34}, Asp^{38}(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH_2 (SEQ ID NO:337);

(Aib^{8,35}, Arg^{26,34}, Asp^{38}(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH_2 (SEQ ID NO:338);

(Aib^{8,35}, Arg^{26,34}, Asp^{38}(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH_2 (SEQ ID NO:339);

(Aib^{8,35,37}, Arg^{26,34}, Asp^{38}(1-(4-decylpiperazine)))hGLP-1(7-38)NH_2 (SEQ ID NO:340);

(Aib^{8,35,37}, Arg^{26,34}, Asp^{38}(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH_2 (SEQ ID NO:341);

(Aib^{8,35,37}, Arg^{26,34}, Asp^{38}(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH_2 (SEQ ID NO:342);

(Aib^{8,35,37}, Arg^{26,34}, Asp^{38}(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH_2 (SEQ ID NO:343);

(Aib^{8,35,} , Arg^{25,34}, Asp^{26}(1-(4-decylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:344);

(Aib^{8,35,} , Arg^{25,34}, Asp^{26}(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:345);

(Aib^{8,35}, Arg^{25,34}, Asp^{26}(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:346);

(Aib^{8,35,} , Arg^{25,34}, Asp^{26}(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:347);

(Aib^{8,35}, Arg^{25,26}, Asp^{34}(1-(4-decylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:348);

(Aib^{8,35}, Arg^{25,26}, Asp^{34}(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:349);

(Aib^{8,35}, Arg^{25,26}, Asp^{34}(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:350);

(Aib^{8,35}, Arg^{25,26}, Asp^{34}(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:351);

(Aib^{8,35}, Arg^{25,26,34}, Asp^{36}(1-(4-decylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:352);

(Aib^{8,35}, Arg^{25,26,34}, Asp^{36}(1-(4-dodecylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:353);

(Aib^{8,35}, Arg^{25,26,34}, Asp^{36}(1-(4-tetradecylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:354);

(Aib^{8,35}, Arg^{25,26,34}, Asp^{36}(1-(4-hexadecylpiperazine)))hGLP-1(7-36)NH_2 (SEQ ID NO:355);

(Aib^{8,35}, Arg^{25,26,34}, Asp^{38}(1-(4-decylpiperazine)))hGLP-1(7-38)NH_2 (SEQ ID NO:356);

(Aib^{8,35}, Arg^{25,26,34}, Asp^{38}(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH_2 (SEQ ID NO:357);

(Aib^{8,35}, Arg^{25,26,34}, Asp^{38}(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH_2 (SEQ ID NO:358);

(Aib^{8,35}, Arg^{25,26,34}, Asp^{38}(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH_2 (SEQ ID NO:359);

(Aib^{8,35,37}, Arg^{25,26,34}, Asp^{38}(1-(4-decylpiperazine)))hGLP-1(7-38)NH_2 (SEQ ID NO:360);

(Aib^{8,35,37}, Arg^{25,26,34}, Asp^{38}(1-(4-dodecylpiperazine)))hGLP-1(7-38)NH_2 (SEQ ID NO:361);

(Aib^{8,35,37}, Arg^{25,26,34}, Asp^{38}(1-(4-tetradecylpiperazine)))hGLP-1(7-38)NH_2 (SEQ ID NO:362);

(Aib^{8,35,37}, Arg^{25,26,34}, Asp^{38}(1-(4-hexadecylpiperazine)))hGLP-1(7-38)NH_2 (SEQ ID NO:363);

(Aib^{8,35}, Arg^{26,34}, Glu^{36}(1-dodecylamino))hGLP-1(7-36)NH_2 (SEQ ID NO:364);

(Aib^{8,35}, Glu^{26}(1-dodecylamino), Arg^{34})hGLP-1(7-36)NH_2 (SEQ ID NO:365);

(Aib^{8,35}, Arg^{26,} , Glu^{34}(1-dodecylamino))hGLP-1(7-36)NH_2 (SEQ ID NO:366);

(Aib^{8,35,37}, Arg^{26,34}, Glu^{38}(1-dodecylamino))hGLP-1(7-38)NH_2 (SEQ ID NO:367);

(Aib^{8,35}, Arg^{34}, Lys^{26}(N$^{\varepsilon}$-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:368);

(Aib^{8,35}, Arg^{34}, Lys^{26}(N$^{\varepsilon}$-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:369);

(Aib^{8,35}, Arg^{34}, Lys^{26}(N$^{\varepsilon}$-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:370;

(Aib^{8,35}, Arg^{34}, Lys^{26}(N$^{\varepsilon}$-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:371);

(Aib^{8,35}, Arg^{26}, Lys^{34}(N$^{\varepsilon}$-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:372);

(Aib^{8,35}, Arg^{26}, Lys^{34}(N$^{\varepsilon}$-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:373);

(Aib^{8,35}, Arg^{26}, Lys^{34}(N$^{\varepsilon}$-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:374);

(Aib^{8,35}, Arg^{26}, Lys^{34}(N$^{\varepsilon}$-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:375);

(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:376);

(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:377);

(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:378);

(Aib^{8,35}, Arg^{26,34}, Lys^{38}(N$^{\varepsilon}$-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2 (SEQ ID NO:379);

(Aib^{8,35}, Arg^{26,34}, Lys^{38}(N$^{\varepsilon}$-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2 (SEQ ID NO:380);

(Aib^{8,35}, Arg^{26,34}, Lys^{38}(N$^{\varepsilon}$-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2 (SEQ ID NO:381);

(Aib^{8,35}, Arg^{26,34}, Lys^{38}(N$^{\varepsilon}$-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2 (SEQ ID NO:382);

(Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N$^{\varepsilon}$-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2 (SEQ ID NO:383);

(Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N$^{\varepsilon}$-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2 (SEQ ID NO:384);

(Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N$^{\varepsilon}$-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2 (SEQ ID NO:385);

(Aib^{8,35,37}, Arg^{26,34}, Lys^{38}(N$^{\varepsilon}$-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2 (SEQ ID NO:386);

(Aib^{8,35}, Arg^{25,34}, Lys^{26}(N$^{\varepsilon}$-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:387);

(Aib^{8,35}, Arg^{25,34}, Lys^{26}(N$^{\varepsilon}$-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:388);

(Aib^{8,35}, Arg^{25,34}, Lys^{26}(N$^{\varepsilon}$-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:389);

(Aib^{8,35}, Arg^{25,34}, Lys^{26}(N$^{\varepsilon}$-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:390);

(Aib^{8,35}, Arg^{25,26}, Lys^{34}(N$^{\varepsilon}$-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:391);

(Aib^{8,35}, Arg^{25,26}, Lys^{34}(N$^{\varepsilon}$-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:392);

(Aib^{8,35}, Arg^{25,26}, Lys^{34}(N$^{\varepsilon}$-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:393);

(Aib^{8,35}, Arg^{25,26}, Lys^{34}(N$^{\varepsilon}$-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:394);

(Aib^{8,35}, Arg^{25,26,34}, Lys^{36}(N$^{\varepsilon}$-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:395);

(Aib^{8,35}, Arg^{25,26,34}, Lys^{36}(N$^{\varepsilon}$-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:396);

(Aib^{8,35}, Arg^{25,26,34}, Lys^{36}(N$^{\varepsilon}$-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:397);

(Aib^{8,35}, Arg^{25,26,34}, Lys^{36}(N$^{\varepsilon}$-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-36)NH_2 (SEQ ID NO:398);

(Aib^{8,35}, Arg^{25,26,34}, Lys^{38}(N$^{\varepsilon}$-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2 (SEQ ID NO:399);

(Aib^{8,35}, Arg^{25,26,34}, Lys^{38}(N$^{\varepsilon}$-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2 (SEQ ID NO:400);

(Aib^{8,35}, Arg^{25,26,34}, Lys^{38}(N$^{\varepsilon}$-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2 (SEQ ID NO:401);

(Aib^{8,35}, Arg^{25,26,34}, Lys^{38}(N$^{\varepsilon}$-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2 (SEQ ID NO:402);

(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N$^{\varepsilon}$-(2-(4-decyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2 (SEQ ID NO:403);

(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N$^{\varepsilon}$-(2-(4-dodecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2 (SEQ ID NO:404);

(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N$^{\varepsilon}$-(2-(4-tetradecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2 (SEQ ID NO:405);

(Aib^{8,35,37}, Arg^{25,26,34}, Lys^{38}(N$^{\varepsilon}$-(2-(4-hexadecyl-1-piperazine)-acetyl)))hGLP-1(7-38)NH_2 (SEQ ID NO:406);

(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:407);

(Aib^{8,35}, Lys^{25}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:408);

(Aib^{8,35}, Arg^{26,34}, Ava^{37}, Ado^{38})hGLP-1(7-38)NH_2 (SEQ ID NO:409);

(Aib[8,35], Arg[26,34], Asp[37], Ava[38], Ado[39])hGLP-1(7-39)NH_2 (SEQ ID NO:27);

(Aib[8,35], Arg[26,34], Aun[37])hGLP-1(7-37)NH_2 (SEQ ID NO:28);

(Aib[8,17,35])hGLP-1(7-36)NH_2 (SEQ ID NO:29);

(Aib[8], Arg[26,34], β-Ala[35], D-Asp[37],Ava[38], Aun[39])hGLP-1(7-39)NH_2 (SEQ ID NO:30);

(Gly[8], β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:31);

(Ser[8], β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:32);

(Aib[8], Glu[22,23], β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:33);

(Gly[8], Aib[35])hGLP-1(7-36)NH_2 (SEQ ID NO:34);

(Aib[8], Lys[18], β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO35);

(Aib[8], Leu[27], β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:36);

(Aib[8], Lys[33], β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:37);

(Aib[8], Lys[18], Leu[27], β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:38);

(Aib[8], D-Arg[36])hGLP-1(7-36)NH_2 (SEQ ID NO:39);

(Aib[8], β-Ala[35], D-Arg[37])hGLP-1(7-37)NH_2 (SEQ ID NO:40);

(Aib[8,27], β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:41);

(Aib[8,27], β-Ala[35,37], Arg[38])hGLP-1(7-38)NH_2 (SEQ ID NO:42);

(Aib[8,27], β-Ala[35,37], Arg[38,39])hGLP-1(7-39)NH_2 (SEQ ID NO:43);

(Aib[8], Lys[18,27], β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:44);

(Aib[8], Lys[27], β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:45);

(Aib[8], β-Ala[35], Arg[38])hGLP-1(7-38)NH_2 (SEQ ID NO:46);

(Aib[8], Arg[26,34], β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:47);

(Aib[8], D-Arg[35])hGLP-1(7-36)NH_2 (SEQ ID NO:48);

(Aib[8], β-Ala[35], Arg[37])hGLP-1(7-37)NH_2 (SEQ ID NO:49);

(Aib[8], Phe[31], β-Ala[35])hGLP-1(7-36)NH_2 (SEQ ID NO:50);

(Aib[8,35], Phe[31])hGLP-1(7-36)NH_2 (SEQ ID NO:51);

(Aib[8,35], Nal[31])hGLP-1(7-36)NH_2 (SEQ ID NO:52);

(Aib[8,35], Nal[28,31])hGLP-1(7-36)NH_2 (SEQ ID NO:53);

(Aib[8,35], Arg[26,34], Nal[31])hGLP-1(7-36)NH_2 (SEQ ID NO:54);

(Aib[8,35], Arg[26,34], Phe[31])hGLP-1(7-36)NH_2 (SEQ ID NO:55);

(Aib[8,35], Nal[19,31])hGLP-1(7-36)NH_2 (SEQ ID NO:56);

(Aib[8,35], Nal[12,31])hGLP-1(7-36)NH_2 (SEQ ID NO:57);

(Aib^{8,35}, Lys^{36}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:58);

(Aib^{8,35}, Arg^{34}, Lys^{26}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:59);

(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-dodecanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:60);

(Aib^{8}, β-Ala^{35}, Ser^{37}(O-decanoyl))hGLP-1(7-37)NH$_2$ (SEQ ID NO:61);

(Aib^{8,27}, β-Ala^{35,37}, Arg^{38}, Lys^{39}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-39)NH$_2$ (SEQ ID NO:62);

(Aib^{8}, Arg^{26,34}, β-Ala^{35}, Lys^{37}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-37)NH$_2$ (SEQ ID NO:63);

(Aib^{8}, Arg^{26,34}, β-Ala^{35}, Lys^{37}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-37)NH$_2$ (SEQ ID NO:64);

(Aib^{8}, Arg^{26,34}, β-Ala^{35}, Lys^{37}(N$^{\varepsilon}$-tetradecanoyl))hGLP-1(7-37)NH$_2$ (SEQ ID NO:65);

(Aib^{8}, Arg^{26,34}, β-Ala^{35}, Lys^{37}(N$^{\varepsilon}$-dodecanoyl))hGLP-1(7-37)NH$_2$ (SEQ ID NO:410); or

(Aib^{8}, Arg^{26,34}, β-Ala^{35}, Lys^{37}(N$^{\varepsilon}$-dodecanoyl))hGLP-1(8-37)NH$_2$ (SEQ ID NO:411);

or a pharmaceutically acceptable salt thereof.

16. A compound according to claim 15 wherein said compound is

(Aib^{8,35}, A6c^{32})hGLP-1(7-36)NH$_2$ (SEQ ID NO:16);

(Aib^{8,35}, Glu^{23})hGLP-1(7-36)NH$_2$ (SEQ ID NO:17);

(Aib ^{8,24,35})hGLP-1(7-36)NH$_2$ (SEQ ID NO:18);

(Aib^{8,35}, Glu^{23}, A6c^{32})hGLP-1(7-36)NH$_2$ (SEQ ID NO:19);

(Aib^{8}, Glu^{23}, β-Ala^{35})hGLP-1(7-36)NH$_2$ (SEQ ID NO:20);

(Aib^{8,35}, Arg^{26,34})hGLP-1(7-36)NH$_2$ (SEQ ID NO:21);

(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:22);

(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:23);

(Aib^{8,35}, Lys^{25}, Arg^{26,34}Lys^{36}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-36)OH (SEQ ID NO:24);

(Aib^{8}, Arg^{26,34}, β-Ala^{35}, Lys^{36}(N$^{\varepsilon}$-Aec-decanoyl))hGLP-1(7-36)NH$_2$ (SEQ ID NO:25);

(Aib^{8,35}, Arg^{26,34}, Ava^{37}, Ado^{38})hGLP-1(7-38)NH$_2$ (SEQ ID NO:26);

(Aib^{8,35}, Arg^{26,34}, Asp^{37}, Ava^{38}, Ado^{39})hGLP-1(7-39)NH$_2$ (SEQ ID NO:27);

(Aib^{8,35}, Arg^{26,34}, Aun^{37})hGLP-1(7-37)NH$_2$ (SEQ ID NO:28);

(Aib^{8,17,35})hGLP-1(7-36)NH$_2$ (SEQ ID NO:29);

(Aib^{8}, Arg^{26,34}, β-Ala^{35}, D-Asp^{37}, Ava^{38}, Aun^{39})hGLP-1(7-39)NH$_2$ (SEQ ID NO:30);

(Gly^{8}, β-Ala^{35})hGLP-1(7-36)NH$_2$ (SEQ ID NO:31);

(Ser^{8}, β-Ala^{35})hGLP-1(7-36)NH$_2$ (SEQ ID NO:32);

(Aib^{8}, Glu^{22,23}, β-Ala^{35})hGLP-1(7-36)NH$_2$ (SEQ ID NO:33);

(Gly^{8}, Aib^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:34);

(Aib^{8}, Lys^{18}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO: 35);

(Aib^{8}, Leu^{27}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:36);

(Aib^{8}, Lys^{33}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:37);

(Aib^{8}, Lys^{18}, Leu^{27}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:38);

(Aib^{8}, D-Arg^{36})hGLP-1(7-36)NH_2 (SEQ ID NO:39);

(Aib^{8}, β-Ala^{35}, D-Arg^{37})hGLP-1(7-37)NH_2 (SEQ ID NO:40);

(Aib^{8,27}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:41);

(Aib^{8,27}, β-Ala^{35,37}, Arg^{38})hGLP-1(7-38)NH_2 (SEQ ID NO:42);

(Aib^{8,27}, β-Ala^{35,37}, Arg^{38,39})hGLP-1(7-39)NH_2 (SEQ ID NO:43);

(Aib^{8}, Lys^{18,27}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:44);

(Aib^{8}, Lys^{27}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:45);

(Aib^{8}, β-Ala^{35}, Arg^{38})hGLP-1(7-38)NH_2 (SEQ ID NO:46);

(Aib^{8}, Arg^{26,34}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:47);

(Aib^{8}, D-Arg^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:48);

(Aib^{8}, β-Ala^{35}, Arg^{37})hGLP-1(7-37)NH_2 (SEQ ID NO:49);

(Aib^{8}, Phe^{31}, β-Ala^{35})hGLP-1(7-36)NH_2 (SEQ ID NO:50);

(Aib^{8,35}, Phe^{31})hGLP-1(7-36)NH_2 (SEQ ID NO:51);

(Aib^{8,35}, Nal^{31})hGLP-1(7-36)NH_2 (SEQ ID NO:52);

(Aib^{8,35}, Nal^{28,31})hGLP-1(7-36)NH_2 (SEQ ID NO:53);

(Aib^{8,35}, Arg^{26,34}, Nal^{31})hGLP-1(7-36)NH_2 (SEQ ID NO:54);

(Aib^{8,35}, Arg^{26,34}, Phe^{31})hGLP-1(7-36)NH_2 (SEQ ID NO:55);

(Aib^{8,35}, Nal^{19,31})hGLP-1(7-36)NH_2 (SEQ ID NO:56);

(Aib^{8,35}, Nal^{12,31})hGLP-1(7-36)NH_2 (SEQ ID NO:57);

(Aib^{8,35}, Lys^{36}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:58);

(Aib^{8,35}, Arg^{34}, Lys^{26}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:59);

(Aib^{8,35}, Arg^{26,34}, Lys^{36}(N$^{\varepsilon}$-dodecanoyl))hGLP-1(7-36)NH_2 (SEQ ID NO:60);

(Aib^{8}, β-Ala^{35}, Ser^{37}(O-decanoyl))hGLP-1(7-37)-NH_2 (SEQ ID NO:61);

(Aib^{8,27}, β-Ala^{35,37}, Arg^{38}, Lys^{39}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-39)NH_2 (SEQ ID NO:62);

(Aib^{8}, Arg^{26,34}, β-Ala^{35}, Lys^{37}(N$^{\varepsilon}$-octanoyl))hGLP-1(7-37)NH_2 (SEQ ID NO:63);

(Aib^{8}, Arg^{26,34}, β-Ala^{35}, Lys^{37}(N$^{\varepsilon}$-decanoyl))hGLP-1(7-37)NH_2 (SEQ ID NO:64); or

(Aib[8], Arg[26,34], β-Ala[35], Lys[37](Nε-tetradecanoyl))hGLP-1(7-37)NH_2 (SEQ ID NO:65);
or a pharmaceutically acceptable salt thereof.

17. Use of a compound as claimed in any of claims 1, 9, or 15, in the preparation of a medicament for the treatment of disease.

18. Use as claimed in claim 17, in which the disease is selected from the group consisting of Type I diabetes, Type II diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis and neurodegenerative disease.